Author

Chinyu Su 1

1 Pfizer Inc,Collegeville,United States

ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE ULCERATIVE COLITIS PROGRAMME FOR TOFACITINIB

Bruce E. Sands, Millie D. Long, Leonard Baidoo, Walter Reinisch, Julian Panés, Chudy I. Nduaka, Arif Soonasra, Ronald D. Pedersen, Nervin Lawendy, Gary Chan, Gary S. Friedman, Chinyu Su

ASSOCIATION BETWEEN DURATION OF LATEST FLARE BEFORE INDUCTION TREATMENT WITH TOFACITINIB AND EFFICACY OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS

Geert D’Haens, Alessandro Armuzzi, Chinyu Su, Xiang Guo, Irene Modesto, Rajiv Mundayat, David P. Hudesman, Michael Chiorean

BASELINE ALBUMIN LEVEL IS NOT A SIGNIFICANT PREDICTOR OF TOFACITINIB EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS OF MULTIVARIATE EXPOSURE-RESPONSE ANALYSIS

Gary R. Lichtenstein, Andrew Tinsley, Xavier Roblin, Tadakazu Hisamatsu, Camille Vong, Shinichi Tsuchiwata, Konstantinos Tsilkos, Haiying Zhang, Arnab Mukherjee, Chinyu Su, David T. Rubin

CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS PROGRAMME: AN UPDATE AS OF MAY 2019

Edward V Loftus Jr., Alessandro Armuzzi, Daniel C. Baumgart, Jeffrey R Curtis, Jami A. Kinnucan, Nana Koram, Leonardo Salese, Chinyu Su, Kenneth Kwok, John Woolcott

EFFICACY AND SAFETY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: AN UPDATE OF RESULTS FROM THE OCTAVE CLINICAL TRIALS

Julian Panés, Jean-Frederic Colombel, Severine Vermeire, Marla C. Dubinsky, Ala I. Sharara, Nervin Lawendy, Wenjin Wang, Leonardo Salese, Chinyu Su, Irene Modesto, Xiang Guo, Edward V. Loftus Jr.

Faecal calprotectin levels, C-reactive protein levels and partial Mayo score as early predictors of clinical and endoscopic outcomes in adult patients with moderately to severely active ulcerative colitis treated with tofacitinib in a Phase 2 study

Marla C. Dubinsky, David P. Hudesman, nicole kulisek, Leonardo Salese, Jerome Paulissen, Chinyu Su, Fernando Magro

HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: AN UPDATE AS OF MAY 2019

Kevin L. Winthrop, Gil Y. Melmed, Severine Vermeire, Nervin Lawendy, Rajiv Mundayat, nicole kulisek, Chinyu Su

Impact of baseline corticosteroid therapy on tofacitinib induction efficacy and infection risk in patients with ulcerative colitis: data from global clinical trials

Gary Lichtenstein, Benjamin L. Cohen, Leonardo Salese, Arif Soonasra, Irene Modesto, Wenjin Wang, Deborah.A Woodworth, Gary Chan, Daniel Quirk, Chinyu Su, Laurent Peyrin‐Biroulet

IMPROVEMENT IN PHYSICIAN'S GLOBAL ASSESSMENT WITHIN 2 WEEKS IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB

Michael Chiorean, David T. Rubin, Mark Lowenberg, Javier Gisbert, Konstantinos Tsilkos, Daniel Quirk, Leonardo Salese, Haiying Zhang, Deborah A. Woodworth, Chinyu Su

Incidence of venous thromboembolic events in patients with ulcerative colitis treated with tofacitinib in the ulcerative colitis clinical development programme

William Sandborn, Julian Panés, Bruce E. Sands, Walter Reinisch, Chinyu Su, Nervin Lawendy, Nana Koram, Haiyun Fan, Thomas V Jones, Irene Modesto, Daniel Quirk, Silvio Danese

Item 1 - 10 / 28
1
2 3